Search Results - "Auby, D."

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials by Barbier, Emilie, François, Eric, Michel, Pierre, Rougier, Philippe, Seitz, Jean-François, Aouakli, A., Bedjaoui, A., Botton, A., Cadier-Lagnes, A., Hollebecque, A., Lemaire, A., Marre, A., Villing, A.L., Denis, B., Becht, C., Bineau, C., Borel, C., Buffet, C., Cornila, C., Couffon, C., Locher, C., Rebischung, C., Sarda, C., Auby, D., Baudet-Klepping, D., Besson, D., Cleau, D., Festin, D., Genet, D., Peré-Vergé, D., Pillon, D., Smith, D., Dorval Danquechin, E., Maillard, E., Mitry, E., Suc, E., Zrihen, E., Pariente, E.A., Dewaele, F., Di Fiore, F., Husseini, F., Kikolski, F., Petit-Laurent, F., Zerouala-Boussaha, F., Caroli-Bosc, F.X., Boilleau-Jolimoy, G., Medinger, G., Graber, I., Charneau, J., Cretin, J., Deguiral, J., Lacourt, J., Meunier, J., Vincent, J., Volet, J., Barbare, J.C., Paitel, J.F., Raoul, J.L., Gornet, J.M., Aucouturier, J.P., Barbieux, J.P., Plachot, J.P., Ramain, J.P., Spano, J.P., Bouhier-Leporrier, K., Cany, L., Rob, L., Baconnier, M., Benchalal, M., Combe, M., Duluc, M., Giovannini, M., Mabro, M., Ramdani, M., Tissot, M., Clavero-Fabri, M.C., Gouttebel, M.C., Kaminsky, M.C., Stremsdoerfer, N., Burtin, P., Cassan, P., Claudé, P., Couzigou, P., Geoffroy, P., Godeau, P., Hammel, P., Novello, P., Prost, P., Ruszniewski, P., Texereau, P., Coriat, R., Nasca, S., Fratte, S.P., Mansourbakht, T., Walter, T., Derias, V., Jestin Le Tallec, V., Sebbagh, V., Adhoute, X., Becouarn, Y.

“…Previous studies showed that high and low body mass index (BMI) was associated with worse prognosis in early-stage colorectal cancer (CRC), and low BMI was…”
Get full text

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial by Bachet, J.B., Lucidarme, O., Levache, C.B., Barbier, E., Raoul, J.L., Lecomte, T., Desauw, C., Brocard, F., Pernot, S., Breysacher, G., Lagasse, J.P., Di Fiore, F., Etienne, P.L., Dupuis, O.J.M., Aleba, A., Lepage, C., Taieb, J., Dahan, L., Auby, D., Khemissa, F., Ghiringhelli, F., Nguyen, S., Bedjaoui, A., Terrebonne, E., Thaury, J., Baconnier, M.

“…The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of…”
Get full text

Impact of circulating biomarkers in patients with metastatic colorectal cancer treated with first-line FOLFOX-aflibercept therapy. Results of the GERCOR VELVET Phase II study by Tijeras-Raballand, A, De Gramont, A, Chiron, M, Bachet, J.B, André, T, Auby, D, Desramé, J, Baba-Ahmed, N, Lecaille, C, Lebrun, V, Louvet, C, Tournigand, C, Benner, S, Attia, M, Bonnetain, F, Chibaudel, B

“…Background: The combination of aflibercept to OPTIMOX (VELVET study) was evaluated in patients with previously untreated advanced colorectal cancer (Chibaudel…”
Get full text

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial by Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J.L., Ychou, M., Legoux, J.L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F.R., Bonnetain, F., Taieb, J., Brucker, P., Landi, B., Flesch, M., Carola, E., Martin, P., Vaillant, E., de Gramont, A.

“…The sequential FOLFOX7–FOLFIRI combination is not superior to FOLFOX4 in colorectal cancer patients with resectable metastases. Patients with synchronous…”
Get full text

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial by Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J.L., Ychou, M., Legoux, J.L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F.R., Bonnetain, F., de Gramont, A.

Get full text

Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial by Pénichoux, J, Michiels, S, Bouché, O, Etienne, P.-L, Texereau, P, Auby, D, Rougier, P, Ducreux, M, Pignon, J.-P

“…Abstract The FFCD 2000–05 randomised trial included 410 patients with advanced colorectal cancer and compared a sequential arm S treated with 5-fluorouracil…”
Get full text

3030 POSTER Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): preliminary results by Ducreux, M, Castaing, M, Etienne, P.L, Texereau, P, Auby, D, Bedenne, L, Rougier, P, Gargot, D, Gasmi, M, Bouché, O

Get full text

390P Impact of age on treatment strategies in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): A prespecified subgroup analysis of the GERCOR-PRODIGE STRATEGIC-1 phase III study by Carola, E., Chibaudel, B., Boulahssass, R., Dourthe, L.M., André, T., Henriques, J., Bourgeois, V., Etienne, P-L., Desrame, J., Dupuis, O., Baba-Hamed, N., Auby, D., Louvet, C., Maillard, E., Tournigand, C., Garcia-Larnicol, M-L., Shacham Shmueli, E., Bird, B.H., Ghiringhelli, F., de Gramont, A.

Get full text

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02) by Aparicio, T., Lavau-Denes, S., Phelip, J.M., Maillard, E., Jouve, J.L., Gargot, D., Gasmi, M., Locher, C., Adhoute, X., Michel, P., Khemissa, F., Lecomte, T., Provençal, J., Breysacher, G., Legoux, J.L., Lepère, C., Charneau, J., Cretin, J., Chone, L., Azzedine, A., Bouché, O., Sobhani, I., Bedenne, L., Mitry, E., Amoyal, P., Auby, D., Bachet, J.B., Baconnier, M., Benoit, R., Berthelet, O., Bidault, A., Bineau, C., Bordes, G., Bouarioua, N., Boucher, E., Boulat, O., Cleau, D., Couzigou, P., Cuillerier, E., Cumin, I., Denis, B., Di Fiore, F., Derias, V., Ezenfis, J., Faroux, R., Gagnaire, A., Gatineau-Sailliant, G., Garcia, B., Genet, D., Gueye, A., Hammel, P., Lagasse, J.P., Landi, B., Lepage, C., Lobry, C., Lombard-Bohas, C., Mabro, M., Mackiewicz, R., Martin, J., Moncoucy, X., Morvan, F., Mozer, M., Pauwels, M., Petit-Laurent, F., Pouderoux, P., Prost, P., Queuniet, A.M., Ramdani, M., Rebischung, C., Rougier, P., Schnee, M., Seitz, J.F., Stefani, L., Taïeb, J., Terrebonne, E., Texereau, P., Thaury, J., Tougeron, D., Weber, A., Ricard, F., Bonnetain, F., Masskouri, F., Choine, C., Guiliani, F., Le Pessec, G., Fattouh, H., Le Provost, N., Girault, C., Schneider, M.

“…Metastatic colorectal cancer (mCRC) frequently occurs in elderly patients. However, data from a geriatric tailored randomized trial about tolerance to and the…”
Get full text

449 - Impact of circulating biomarkers in patients with metastatic colorectal cancer treated with first-line FOLFOX-aflibercept therapy. Results of the GERCOR VELVET Phase II study by Tijeras-Raballand, A., De Gramont, A., Chiron, M., Bachet, J.B., André, T., Auby, D., Desramé, J., Baba-Ahmed, N., Lecaille, C., Lebrun, V., Louvet, C., Tournigand, C., Benner, S., Attia, M., Bonnetain, F., Chibaudel, B.

Get full text

Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study by Gouverneur, Amandine, Coutureau, Juliette, Jové, Jérémy, Rouyer, Magali, Grelaud, Angela, Duc, Sophie, Gérard, Stéphane, Smith, Denis, Ravaud, Alain, Droz, Cécile, Bernard, Marie-Agnès, Lassalle, Régis, Forrier-Réglat, Annie, Noize, Pernelle, Smith, D., Tubiana-Mathieu, N., Michel, P., Guimbaud, R., Becouarn, Y., Viret, F., Larregain-Fournier, D., Botreau, Y., Texereau, P., Auby, D., Gautier-Felizot, L., Loury-Larivière, I., Brudieux, E., Cany, L., Lecaille, C., Jaubert, D., Guichard, P., Bernard, O., Vives, L., Taoubi, N., Martinez, M., Burki, F., Roque, I., Thouveny, F., Gaspard, M.H.

“…Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and…”
Get full text

Phase II study of FOLFIRI chemotherapy as first-line treatment for elderly patients (pts) with advanced gastric cancer (AGC) by Becouarn, Y., Bellera, C., Brunet, R., Legoux, J., Cany, L., Dauba, J., Smith, D., Auby, D., Mertens, C., Fonck, M.

“…Abstract only…”
Get full text

Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: Results of the ETNA cohort study by Terrebonne, E., Smith, D., Becouarn, Y., Michel, P., Guimbaud, R., Auby, D., sa Cunha, A., Ravaud, A., Rouyer, M., Fourrier-Réglat, A.

“…Abstract only…”
Get full text

Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): Preliminary results by Bouché, O., Castaing, M., Etienne, P. L., Texereau, P., Auby, D., Bedenne, L., Rougier, P., Gargot, D., Gasmi, M., Ducreux, M.

“…Abstract only 4069 Background: The survival benefit of using a combination therapy instead of keeping it for a second line (L2) has not been demonstrated in…”
Get full text

Esophageal ulcer related to ingestion of Inod'Ail (allyl sulfide) by Auby, D M, Baldit, C P

Get more information

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial by Ducreux, Michel, Prof, Malka, David, MD, Mendiboure, Jean, MSc, Etienne, Pierre-Luc, MD, Texereau, Patrick, MD, Auby, Dominique, MD, Rougier, Philippe, Prof, Gasmi, Mohamed, MD, Castaing, Marine, MSc, Abbas, Moncef, MD, Michel, Pierre, Prof, Gargot, Dany, MD, Azzedine, Ahmed, MD, Lombard-Bohas, Catherine, MD, Geoffroy, Patrick, MD, Denis, Bernard, MD, Pignon, Jean-Pierre, MD, Bedenne, Laurent, Prof, Bouché, Olivier, Prof

“…Summary Background The optimum use of cytotoxic drugs for advanced colorectal cancer has not been defined. Our aim was to investigate whether combination…”
Get full text

4.62 A SIX-MONTH OPEN-LABEL EXTENSION STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS by Findling, Robert L., MD, MBA, Robb, Adelaide S., MD, DelBello, Melissa P., MD, MS, Huss, Michael, MD, McNamara, Nora K., MD, Sarkis, Elias H., MD, Scheffer, Russell E., MD, Poulsen, Lis H., MD, Chen, Grace, PhD, Lemming, Ole M., MSc, Auby, Philippe, MD

“…Objectives: This 24-week open-label extension (OLE) of NCT01491035 (14- day, open-label, multidose, pharmacokinetic/safety study) investigated the long-term…”
Get full text

CO.136 Etudes statistiques complémentaires de l’essai stratégique FFCD 2000-05 : une monochimiothérapie d’emblée ne fait pas courir de risque au patients ayant un cancer colorectal métastasé by Pénichou, J., Ducreux, M., Bouché, O., Etienne, P.L., Texereau, P., Auby, D., Bedenne, L., Rougier, P., Pignon, J.P., Gargot, D., Gasmi, M., Michiels, S.

“…L’essai FFCD 2000-05 a évalué deux stratégies de chimiothérapie dans le traitement du cancer colorectal métastasé. Ces deux stratégies se sont révélées…”
Get full text